Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells

被引：318

作者：

Muranen, Taru ^{[1
]}

Selfors, Laura M. ^{[1
]}

Worster, Devin T. ^{[1
]}

Iwanicki, Marcin P. ^{[1
]}

Song, Loling ^{[1
]}

Morales, Fabiana C. ^{[2
]}

Gao, Sizhen ^{[1
]}

Mills, Gordon B. ^{[2
]}

Brugge, Joan S. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA

来源：

CANCER CELL | 2012年 / 21卷 / 02期

基金：

芬兰科学院;

关键词：

CAP-INDEPENDENT TRANSLATION; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; INSULIN-RECEPTOR; AKT ACTIVATION; UP-REGULATION; PI3K PATHWAY; BREAST; INITIATION; APOPTOSIS;

D O I：

10.1016/j.ccr.2011.12.024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The PI3K/mTOR-pathway is the most commonly dysregulated pathway in epithelial cancers and represents an important target for cancer therapeutics. Here, we show that dual inhibition of PI3K/mTOR in ovarian cancer-spheroids leads to death of inner matrix-deprived cells, whereas matrix-attached cells are resistant. This matrix-associated resistance is mediated by drug-induced upregulation of cellular survival programs that involve both FOXO-regulated transcription and cap-independent translation. Inhibition of any one of several upregulated proteins, including BcI-2, EGFR, or IGF1R, abrogates resistance to PI3K/mTOR inhibition. These results demonstrate that acute adaptive responses to PI3K/mTOR inhibition in matrix-attached cells resemble well-conserved stress responses to nutrient and growth factor deprivation. Bypass of this resistance mechanism through rational design of drug combinations could significantly enhance PI3K-targeted drug efficacy.

引用

页码：227 / 239

页数：13

共 50 条

[1] Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells
Muranen, T.
Selfors, L.
Iwanicki, M.
Mills, G. B.
Brugge, J. S.
MOLECULAR BIOLOGY OF THE CELL, 2012, 23
[2] Inhibition of PI3K/mTOR leads to adaptive resistance in extracellular matrix attached cancer cells
Muranen, Taru E.
Selfors, Laura
Worster, Devin
Iwanicki, Marcin
Song, Loling
Moriaes, Fabiana
Mills, Gordon B.
Brugge, Joan S.
CANCER RESEARCH, 2012, 72
[3] Adaptive resistance of patient-derived ovarian cancer cells to PI3K/mTOR inhibition
Zervantonakis, Ioannis
Chen, Hsing-Yu
Muranen, Taru
Liu, Joyce
Drapkin, Ronny
Matulonis, Ursula
Brugge, Joan
CLINICAL CANCER RESEARCH, 2015, 21
[4] Inhibition of the PI3K and mTOR pathways reverses gemcitabine resistance in pancreatic cancer
Chung, Vincent
Gaur, Shikha
Ann, David
Yen, Yun
CANCER RESEARCH, 2011, 71
[5] PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy
Liu, Hua
Zhang, Liqin
Zhang, Xuyan
Cui, Zhumei
ONCOTARGETS AND THERAPY, 2017, 10 : 2865 - 2871
[6] Determinants of acquired resistance to PI3K/mTOR inhibition in cells refractory to EGFR inhibition.
Koh, King Xin
Bhattacharya, Bhaskar
Loh, Joanne
Ng, Hong Kiat
Soo, Ross
Iacopetta, Barry
Soong, Richie
CANCER RESEARCH, 2013, 73 (08)
[7] Inhibition of PI3K/Akt partially leads to the inhibition of PrPC-induced drug resistance in gastric cancer cells
Liang, Jie
Ge, Fulin
Guo, Changcun
Luo, Guanhong
Wang, Xin
Han, Guohong
Zhang, Dexin
Wang, Jianhong
Li, Kai
Pan, Yanglin
Yao, Liping
Yin, Zhanxin
Guo, Xuegang
Wu, Kaichun
Ding, Jie
Fan, Daiming
FEBS JOURNAL, 2009, 276 (03) : 685 - 694
[8] DUAL INHIBITION OF PI3K AND mTOR LEADS TO GLIOMA RADIO-SENSITIZATION
Narayan, R. S.
Renwarin, L.
van den Berg, J.
Franken, N. A. P.
Stalpers, L. J. A.
Baumert, B. G.
Sminia, P.
NEURO-ONCOLOGY, 2012, 14 : 89 - 89
[9] Hypoxia leads to deregulation of PI3K/AKT/mTOR signaling in prostate cancer stem cells
Marhold, Maximilian
Tomasich, Erwin
Pernicova, Zuzana
Fedr, Radek
Soucek, Karel
Spittler, Andreas
Krainer, Michael
Horak, Peter
CANCER RESEARCH, 2014, 74 (19)
[10] Stroma-driven resistance to PI3K/mTOR inhibition.
Muranen, Taru
MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 16 - 16

← 1 2 3 4 5 →